What is the price-to-earnings ratio of Haemato?
The price-earnings ratio of Haemato is currently 0.35.
Haemato P/S 2024
Haemato P/S
0.35
Ticker
HAEK.HM
ISIN
DE000A289VV1
WKN
A289VV
As of Nov 1, 2024, Haemato's P/S ratio stood at 0.35, a -7.89% change from the 0.38 P/S ratio recorded in the previous year.
The Haemato P/S history
Haemato Aktienanalyse
What does Haemato do?
Haemato AG is a German company specializing in the trade of high-quality pharmaceuticals and medical products. It was founded in 1993 and has become one of the leading companies in this field. The company's goal is to offer quality medications and medical products for the German market. They carefully select products and collaborate with renowned manufacturers and suppliers to ensure success. Haemato AG is divided into different divisions specializing in the trade of various pharmaceuticals and medical products for oncology, pain therapy, rheumatology, and dermatology. They collaborate with Pfizer, Roche, and Merck for oncology medications. For pain therapy, they offer a range of products including pain relievers and specialized therapies. In rheumatology, they focus on diseases of the musculoskeletal system such as osteoporosis and arthritis. They provide a wide range of medications and medical products tailored to these diseases. In dermatology, they specialize in treating skin conditions such as psoriasis and eczema, offering a variety of medications and medical products. They also offer other products including medical devices like injection needles, syringes, EKG machines, and ultrasound devices. Their business model is based on close collaboration with leading manufacturers and suppliers to ensure high-quality products. They also prioritize comprehensive consultation and support for their customers to ensure they receive the right products for their specific needs. In summary, Haemato AG is a leading company in the pharmaceutical and medical product trade, offering a wide range of products and collaborating with top manufacturers and suppliers to provide high-quality and comprehensive solutions for medical needs. Haemato ist eines der beliebtesten Unternehmen auf Eulerpool.com.P/S Details
Decoding Haemato's P/S Ratio
Haemato's Price to Sales (P/S) Ratio is a crucial financial metric that measures the company's market valuation relative to its total sales revenue. It's calculated by dividing the company's market capitalization by its total sales over a specific period. A lower P/S ratio can indicate that the company is undervalued, while a higher ratio may suggest overvaluation.
Year-to-Year Comparison
Comparing Haemato's P/S ratio yearly provides insights into how the market perceives the company’s value relative to its sales. An increasing ratio over time can indicate growing investor confidence, while a decreasing trend might reflect concerns about the company’s revenue generation capabilities or market conditions.
Impact on Investments
The P/S ratio is instrumental for investors evaluating Haemato's stock. It offers insights into the company’s efficiency in generating sales and its market valuation. Investors use this ratio to compare similar companies within the same industry, aiding in selecting stocks that offer the best value for investment.
Interpreting P/S Ratio Fluctuations
Variations in Haemato’s P/S ratio can result from changes in the stock price, sales revenue, or both. Understanding these fluctuations is crucial for investors to evaluate the company’s current valuation and future growth potential, aligning their investment strategies accordingly.
Frequently Asked Questions about Haemato stock
How has the price-earnings ratio of Haemato changed compared to last year?
The price-to-earnings ratio of Haemato has increased by -7.89% fallen (meaning "decreased" or "dropped") compared to last year.
What consequences does a high price-earnings ratio have for investors?
A high price-to-earnings ratio indicates that the company's stock is relatively expensive and investors may potentially achieve a lower return.
What does a low price-earnings ratio mean?
A low price-earnings ratio means that the company's stock is relatively cheap and investors may potentially achieve a higher return.
Is the price-earnings ratio of Haemato high compared to other companies?
Yes, the price-to-earnings ratio of Haemato is high compared to other companies.
How does an increase in the price-earnings ratio of Haemato affect the company?
An increase in the price-earnings ratio of Haemato would lead to a higher market capitalization of the company, which in turn would lead to a higher valuation of the company.
How does a reduction in the price-to-earnings ratio of Haemato affect the company?
A decrease in the price-earnings ratio of Haemato would result in a lower market capitalization of the company, which in turn would lead to a lower valuation of the company.
What are some factors that influence the price-earnings ratio of Haemato?
Some factors that influence the price-earnings ratio of Haemato are the company's growth, financial position, industry development, and the overall economic situation.
How much dividend does Haemato pay?
Over the past 12 months, Haemato paid a dividend of 1.1 EUR . This corresponds to a dividend yield of about 7.72 %. For the coming 12 months, Haemato is expected to pay a dividend of 1.12 EUR.
What is the dividend yield of Haemato?
The current dividend yield of Haemato is 7.72 %.
When does Haemato pay dividends?
Haemato pays a quarterly dividend. This is distributed in the months of August, August, August, August.
How secure is the dividend of Haemato?
Haemato paid dividends every year for the past 0 years.
What is the dividend of Haemato?
For the upcoming 12 months, dividends amounting to 1.12 EUR are expected. This corresponds to a dividend yield of 7.83 %.
In which sector is Haemato located?
Haemato is assigned to the 'Health' sector.
Wann musste ich die Aktien von Haemato kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Haemato from 7/21/2023 amounting to 1.2 EUR, you needed to have the stock in your portfolio before the ex-date on 7/19/2023.
When did Haemato pay the last dividend?
The last dividend was paid out on 7/21/2023.
What was the dividend of Haemato in the year 2023?
In the year 2023, Haemato distributed 1.1 EUR as dividends.
In which currency does Haemato pay out the dividend?
The dividends of Haemato are distributed in EUR.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von Haemato
Our stock analysis for Haemato Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Haemato Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.